- Doctors & Departments
- Conditions & Advice
- Your Visit
- Research & Innovation
The bone marrow transplant survival rate measure is defined as the percentage of patients who received blood-forming (hematopoietic) stem cell transplants who have survived over the indicated period of time. The data is further broken down by the stem cell source: either from the patient (autologous) or from another donor (allogeneic).
At the Pediatric Bone Marrow Transplantation Program at Children's Hospital Colorado, we measure bone marrow transplant success rates to better understand the effectiveness of treatments used to improve patient outcomes. A major part of these analyses is determining rates of recurrence of the diseases for which transplants were done and rates of severe complications post-transplant. These evaluations let us know where best to put our efforts in improving overall transplant outcomes. This is all part of our efforts to provide the best care for babies, kids and adolescents with cancer and nonmalignant blood diseases.
To understand our pediatric bone marrow transplant program's performance versus international standards, we participate in the Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of survival rates. CIBMTR matches our Children’s Colorado transplant patients to similar patients transplanted elsewhere around the world, taking into account key patient variables such as age, disease and donor type.
The most recent CIBMTR analysis was performed on transplants performed at Children’s Colorado from Jan. 1, 2012 through Dec. 31, 2014 using related and unrelated donors. It only included patients who underwent their first allogeneic transplant (from another donor) within these time periods and who had at least 100 days of post-transplant follow-up.
Children's Colorado reported survival status data for 76 patients. The actual one-year survival of these patients was 76.3%. The predicted one-year survival range was 64.8% and 83.5%. This means that the BMT Program at Children's Colorado had very good one-year survival within the predicted range for a similar group of patients transplanted at other pediatric centers in the United States.
Annually since 2010, CIBMTR has conducted these analyses of each participating center’s allogeneic transplant survival versus international standards. Over the five years of these analyses, the Children’s Colorado BMT Program has always met or exceeded international standards.
Below is a graph of the 30-day, 100-day and one-year survival rates of 322 patients. These patients all received bone marrow transplants at Children’s Colorado between 2007 (when we moved to our new Aurora facility on Anschutz Medical Campus) and the end of 2015.
We have been able to improve BMT patient survival and other outcomes through participation in local, national and international clinical trials evaluating new approaches to pediatric BMT.
In addition, since 2000, our program has had a comprehensive quality assurance (QA) program that looks at performance on an ongoing basis. The BMT Quality Assurance Program at the Children’s Hospital Colorado/ University of Colorado School of Medicine operates in accordance with national guidelines established by the Foundation for Accreditation of Cellular Therapy (FACT). The Pediatric BMT Program at Children’s Colorado has been FACT-approved continuously since 2001.
We have also made patient safety at Children’s Colorado a high-priority team effort by including all providers and caregivers, including patients and families.